Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes

Stopped early · Phase 2

Conditions studied: Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have myelodysplastic syndromes.

Key facts

Study ID

NCT00020969

Run by

CTI BioPharma

Starts

2001-03-01

Expected to finish

2005-01-01

Last updated by the study team

2020-10-05

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Arizona Cancer Center at University of Arizona Health Sciences Center — Tucson, Arizona, United States
• Green Cancer Center at Scripps Clinic — La Jolla, California, United States
• USC/Norris Comprehensive Cancer Center and Hospital — Los Angeles, California, United States
• Jonsson Comprehensive Cancer Center, UCLA — Los Angeles, California, United States
• St. Joseph Hospital Regional Cancer Center - Orange — Orange, California, United States
• Lynn Regional Cancer Center West — Boca Raton, Florida, United States
• Georgia Cancer Specialists - Northside Office — Atlanta, Georgia, United States
• Corpus Christi Cancer Center — Corpus Christi, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.